Bruker Launches New nanoElute® 2 nano-LC For 4D-Proteomics, Advances Fluxomics Applications with MetaboScape®
August 29 2022 - 6:00AM
Business Wire
- New nanoElute 2 features nano-LC advances, supports
automated single cell sample preparation from label-free ProteoCHIP
on CellenONE platform
- MetaboScape® 2023 advances fluxomics applications and
ion mobility offset mass aligned (‘MOMA’) events for
high-throughput 4D-Metabolomics
- Advances in MALDI HiPLEX-IHC™ workflows, and in PaSER™
on-the-fly intelligent acquisition software for
4D-Metaproteomics
At the International Mass Spectrometry Conference (IMSC 2022),
Bruker Corporation (Nasdaq: BRKR) today announced the launch of the
new nanoElute® 2 nano-LC, of MetaboScape® and TASQ® 2023 software
supporting fluxomics, and of latest advances in PaSER™’s
intelligent acquisition to enhance research in protein-protein
interactions (PPIs) and metaproteomics applications.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220829005210/en/
The nanoElute® 2, a high-performance
nanoflow liquid chromatography system with an intuitive and
flexible user interface, covering a broad range of applications
from single cell to high throughput routine proteomics (Photo:
Business Wire)
The next-generation nanoElute® 2 combines outstanding
nano-LC chromatography performance with hardened high-pressure
switching valves, and finger-tight torque-limiting capillaries for
leak-free zero dead volume connections, without the risk of
overtightening or damaging capillaries. The nanoElute 2 features a
further improved nano-LC pump design, and an intuitive and flexible
user interface covering a broad range of applications from
single-cell proteomics to plasma proteomics. The nanoElute 2 now
also supports the label-free ProteoCHIP® for the CellenONE platform
for high-sensitivity single cell proteomics.
Dr. Henrik Johansson, Senior Scientist in Cancer
Proteomics in the Department of Oncology-Pathology at the
Karolinska Institute in Sweden, said: “The ‘dissolve’ workflow on
the nanoElute 2 now perfectly supports our proteomics sample
preparation done by the robotic platform in 96 or 384 well plates.
The nanoElute 2 dissolves the tryptic peptides directly in the
plate prior to injection, avoiding manual intervention and thus
streamlining our workflows.”
The latest MetaboScape 2023 release provides streamlined
collision cross section (CCS)-enabled metabolic profiling and
annotation workflows covering 4D timsTOF data acquisition to
highest confidence annotations for lipids and metabolites. New
features include improved 4D peak detection and integration,
accelerated processing, and smart merging of positive and negative
ion data. Powerful automated prediction of CCS values from chemical
structures in spectral libraries leverages the accurate CCS values
measured on the timsTOF.
In addition, to support the metabolomics community focus on
quality, MetaboScape 2023 now offers better means for data quality
assessment in large scale studies, while TASQ 2023 extends target
screening and quantitation by CCS-enabled MOMA events. Finally,
refinements to stable isotope labeling methods simplify large-scale
labeling experiments.
Professor Nils Faergeman, Department of Biochemistry and
Molecular Biology at the University of Southern Denmark, commented:
“The new TASQ fluxomics workflow streamlined our stable isotope
labeling experiments on our timsTOF instrument. The integrated
natural abundance correction and fractional enrichment calculations
together with manual review capabilities enables us to generate
results with high confidence for our small molecule isotope tracing
studies.”
At IMSC, Buker also showcases the new MALDI HiPLEX-IHC
workflow for multiplex imaging of protein targets. MALDI HiPLEX-IHC
combines Bruker’s IntelliSlides® automated MALDI workflow with
AmberGen’s Miralys antibody-based photocleavable mass tags for
spatial localization of target proteins across tissue sections. Key
advantages of the workflow include whole slide field-of-view and
multiplexing capability of tens to over a hundred protein targets
from FFPE or fresh frozen tissue sections, as well as multiomics
capability to overlay metabolite, lipid and glycan mass spec images
with protein targets from the same section.
Dr. Ron Heeren, Distinguished Professor and Limburg
co-chair of the Maastricht Multimodal Molecular Imaging (M4I)
Institute, added: “At M4I, we develop workflows and techniques to
contextualize the role of individual cells in disease, and
determine how interactions between cells affect cellular states
locally and across long distances. MALDI HiPLEX-IHC provides a
seamless platform for integrating protein expression information
into the key projects that we are collaborating on with our
experimental pathology team.”
At IMSC, Bruker also further advances its bioinformatics
proteomics real-time search capabilities using PaSER™. Intelligent
instrument control leveraging the 4th dimension of large-scale
accurate CCS data promises significantly greater insights, from
post-translational modifications of the epiproteome, to
substoichiometric analytes in targeted approaches.
Dr. Mathieu Lavallée-Adam, Associate Professor at
University of Ottawa and Ottawa Institute of Systems Biology in
Ottawa, Canada, said: “We use machine learning, such as Bayesian
inference, artificial neural networks and logistic regression
classifiers, with large-scale proteomics data to derive biological
knowledge about cellular mechanisms and disease processes.
Biological samples are often sample-limited, thus requiring as much
information to be extracted in single analyses now augmented with
on-the-fly adjustments of mass spectrometry parameters. Bruker’s
intelligent feedback control via PaSER allows us to rapidly
prototype feedback-based bioinformatics modules to be used by the
community. We are enthusiastic to collaborate with Bruker to
further feedback-based intelligent acquisition for the study of
protein-protein interactions and metaproteomics.”
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high performance scientific instruments and high
value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular, and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity, and customer success in life
science molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. Please visit www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220829005210/en/
Media Petra Scheffer Bruker Daltonics Marketing
Communications T: +49 (421) 2205-2843 E: petra.scheffer@bruker.com
Investor Relations Justin Ward Sr. Director Investor
Relations & Corp Development T: +1 (978) 663–3660, ext. 1479 E:
Investor.Relations@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Apr 2023 to Apr 2024